このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Family Connections Transdiagnostic for Relatives of People With Emotional Dysregulation (FC-T)

2026年5月22日 更新者:Verónica Guillén-Botella、University of Valencia

Family Connections Transdiagnostic: Study Protocol for a Randomized Controlled Trial Evaluating Efficacy in Relatives of People With Emotional Dysregulation

The aim of this study is to evaluate the efficacy of the Family Connections Transdiagnostic (FC-T) program in relatives of individuals with psychological disorders associated with emotional dysregulation through a randomized controlled trial.

調査の概要

詳細な説明

Emotional dysregulation (ED) is a core transdiagnostic process characterized by heightened emotional sensitivity, intense emotional responses, and difficulties returning to baseline emotional states. It is present across a wide range of psychological disorders, including eating disorders (EDs), Cluster B personality disorders (PD), and disruptive, impulse-control, and conduct disorders. These conditions are associated with significant impairments in social functioning and are often accompanied by psychological symptoms such as depression, anxiety, interpersonal difficulties, and reduced quality of life. In addition, maladaptive strategies to cope with emotional distress (e.g., self-harm, impulsivity, aggression, binge eating) contribute to the maintenance and severity of these disorders.

Families of individuals with psychological disorders characterized by ED experience a high burden of illness and frequently report elevated levels of psychological distress, including anxiety and depression, as well as impairments in their own quality of life. Despite their key role as primary caregivers, family members often lack the necessary skills to effectively manage emotional crises and daily challenges, which may contribute to dysfunctional family dynamics and increased conflict. Although some intervention programs have been developed for caregivers of specific disorders, there is currently a lack of transdiagnostic treatments specifically designed for relatives of individuals with ED.

A skills training program called "Family Connections" (FC) was developed by Hoffman and Fruzzetti's group for relatives of individuals with borderline personality disorder (BPD). It is a program consisting of 12 weekly two-hour sessions delivered in a group format. It is divided into six modules that include psychoeducation about the disorder and its impact on family functioning, as well as skills adapted from Dialectical Behavior Therapy, such as mindfulness, emotion regulation, validation, radical acceptance, and problem management, among others. In addition, all modules include practical exercises, video examples, and homework assignments. Previous studies have shown that this program leads to significant reductions in caregiver burden, perceived distress, depression, and anxiety, as well as improvements in coping strategies and family functioning.

The present study aims to develop and evaluate a transdiagnostic adaptation of the program (Family Connections Transdiagnostic; FC-T), designed to be applied to relatives of individuals with psychological disorders characterized by emotional dysregulation, regardless of specific diagnosis. The psychoeducational modules will be adapted to address ED as a common underlying mechanism, while maintaining the core skills training components of the original program.

The aims of this study are the following: (a) to adapt and test, in the Spanish population, the modules of the FC-T intervention protocol for relatives of patients with psychological disorders characterized by ED; (b) to test the efficacy of FC-T in reducing caregiver burden and clinical symptomatology and improving family relationships and quality of life; (c) to test its efficiency, understood as the acceptance of the intervention program by participants and clinicians, and to demonstrate its feasibility; and (d) to carry out an effective dissemination of this protocol.

This paper presents the study protocol. The study design consists of a two-arm randomized controlled trial with two conditions: Family Connections Transdiagnostic (FC-T) or Treatment as usual optimized (TAU-O). Participants will be family members of patients diagnosed, according to the 5th version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), with eating disorders, Cluster B personality disorders, or disruptive, impulse-control, and conduct disorders. The caregivers' primary outcome measures will be the Burden Assessment Scale (BAS) and a Family-Patient Critical Incident Record. Secondary outcomes will include measures of family functioning, clinical symptomatology, coping strategies, and quality of life. Patient-related outcomes will include measures of emotional dysregulation and impulsivity. Participants will be assessed at pre-treatment, post-treatment, and twelve-month follow-up. The intention-to-treat principle will be used when analyzing data, using mixed-effects models with full information and maximum likelihood estimation.

研究の種類

介入

入学 (推定)

172

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Valencia
      • Valencia、Valencia、スペイン、46010
        • University of Valencia

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • • Being 18 years of age or older.

    • Being a family member (e.g., parent, partner, sibling, or other close relative) of a patient diagnosed, according to the 5th version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), with a psychological disorder characterized by emotional dysregulation (e.g., eating disorders, Cluster B personality disorders, or disruptive, impulse-control, and conduct disorders).
    • The patient must currently be receiving treatment in a participating clinical center.
    • Having sufficient knowledge and understanding of the Spanish language to complete the assessments and participate in the intervention.
    • Providing written informed consent to participate in the study.

Exclusion Criteria:

  • • Presence of any severe mental disorder or condition in the family member that may interfere with participation in the intervention (e.g., psychotic disorders, schizophrenia, severe cognitive impairment, or intellectual disability).

    • Current substance dependence that may hinder participation in the study.
    • Severe clinical instability in the patient that prevents the family member from participating in the intervention (as judged by clinicians).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Family Connections Transdiagnostic for relatives of people with emotional dysregulation

- 12 weekly group sessions (2 hours each)

Modules:

  1. Introduction and psychoeducation on ED
  2. Development and explanatory models of ED
  3. Emotional regulation and mindfulness
  4. Acceptance and family environment improvement
  5. Communication and validation
  6. Problem-solving
The intervention lasts 3 months and includes 12 two-hour sessions in a group format on a weekly basis. The FC-T program is divided into 6 modules: 2 modules of psychoeducation on emotional dysregulation (ED) and 4 modules of Dialectical Behavior Therapy (DBT)-based skills training (relationship mindfulness, emotional regulation, acceptance, validation, and problem management).
アクティブコンパレータ:Optimized Treatment as Usual (TAU-O)
Usual care + psychoeducational session on ED
Family members will receive the usual care available in their clinical setting. In addition, they will participate in a single 3-hour group psychoeducation session including the following components: (1) up-to-date information and research on emotional dysregulation (epidemiology, frequency, comorbidity, risk and protective factors); and (2) psychoeducation on the development of emotional dysregulation, explanatory models, and available treatments.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Record of critical family-patient incidents
時間枠:Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
Frequency of problem behaviors in the past 3 months, including suicide attempts, self-harm episodes, visits to psychiatric emergency services, episodes of binge eating, substance use (alcohol or drugs), stealing, fire-setting, verbal aggression, and physical aggression.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
Burden Assessment Scale (BAS)
時間枠:Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
It is a 19-item scale that assesses the caregiver's objective and subjective burden due to the illness of their relative within the past six months using a 4-point Likert scale ranging from 1 (not at all) to 4 (a lot). Higher scores indicate greater caregiver burden. The scale shows adequate validity and reliability, with Cronbach's alpha coefficients ranging from .89 to .91.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up

二次結果の測定

結果測定
メジャーの説明
時間枠
Family Assessment Device - Global Functioning Scale (FAD-GF)
時間枠:Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
It is a 60-item self-report measure of family functioning assessing domains such as communication, roles, affective involvement, and general functioning. Items are rated on a 4-point Likert scale. The instrument shows good internal consistency, with Cronbach's alpha coefficients ranging between .72 and .83 for subscales and around .92 for general functioning.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
Depression, Anxiety and Stress Scale (DASS-21)
時間枠:Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
It is a 21-item scale that measures clinical symptoms such as depression, anxiety, and stress. Items are rated on a 4-point Likert scale ranging from 0 (did not apply to me) to 3 (applied to me most of the time). It shows excellent internal consistency, with Cronbach's alpha coefficients of approximately .94 for depression, .87 for anxiety, and .91 for stress.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
Quality of Life Index (QLI)
時間枠:Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
This instrument assesses perceived quality of life across several domains, including health, psychological well-being, and social relationships. Higher scores indicate better quality of life. The Spanish version has demonstrated adequate reliability and validity, with good internal consistency indices.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
Mastery and Empowerment Scale (MES)
時間枠:Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
It is a 34-item scale that evaluates coping strategies, perceived control, and empowerment across family, service system, and community domains. Items are rated on a 5-point Likert scale. Previous studies have demonstrated robust psychometric properties, including good internal consistency and construct validity across different samples.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
Opinion of Treatment Scale
時間枠:Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
This scale assesses participants' satisfaction, acceptance, and perceived usefulness of the intervention program. It evaluates aspects such as satisfaction, perceived effectiveness, and willingness to recommend the program. Items are rated on a Likert-type scale ranging from 0 to 10. This measure has been adapted from previous treatment opinion scales and shows adequate face validity for assessing treatment acceptability.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up

その他の成果指標

結果測定
メジャーの説明
時間枠
Difficulties in Emotion Regulation Scale (DERS) (for Patients)
時間枠:Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
It is a self-report measure assessing difficulties in emotion regulation. The Spanish adaptation includes 28 items across five dimensions (lack of emotional control, interference in goal-directed behavior, lack of emotional awareness, emotional confusion, and emotional rejection). Items are rated on a Likert scale from 1 to 5. The scale shows very good internal consistency (Cronbach's alpha ≈ .93) and good test-retest reliability (r ≈ .74).
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
Barratt Impulsiveness Scale (BIS) (for Patients)
時間枠:Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
This instrument assesses impulsivity as a multidimensional construct, including attentional, motor, and non-planning impulsivity. Items are rated on a Likert-type scale. The Spanish adaptation has demonstrated adequate psychometric properties, including good internal consistency and construct validity.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
Family Assessment Device - Global Functioning Scale (FAD-GF) (for Patients)
時間枠:Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
It is a self-report measure of family functioning assessing domains such as communication, roles, affective involvement, and general functioning. It shows good internal consistency, with Cronbach's alpha coefficients ranging from .72 to .83 and up to .92 for general functioning.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
Validating and Invalidating Responses Scale (VIRS) (for Patients)
時間枠:Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
It is a 16-item scale that assesses perceived validation and invalidation in caregiver responses. Items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (almost always). The scale has shown adequate internal consistency and construct validity in previous studies.
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
Lum Emotional Availability of Parents (LEAP) (for Patients)
時間枠:Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up
It is a 15-item questionnaire that assesses perceived emotional availability of caregivers. Items are rated on a 6-point Likert scale. The instrument shows excellent internal consistency (Cronbach's alpha ≈ .92 for mothers and .93 for fathers) and good test-retest reliability (r ≈ .92 and r ≈ .85, respectively).
Changes will be assessed from pre-treatment to immediately after the intervention, and also at 12-month follow-up

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディチェア:Laura Díaz-Sanahuja, Dr. Professor、University of Valencia
  • スタディチェア:Cayetana Garoz, PhD、University of Castellón
  • スタディチェア:Álvaro Cadiñanos, PhD、University of Valencia
  • スタディチェア:Elena González-Perpiñá, PhD、University of Valencia
  • スタディチェア:Antonio Arnal, PhD、University of Valencia
  • スタディチェア:Ginnette Muñoz, PhD、University of Valencia

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年5月3日

一次修了 (推定)

2026年12月25日

研究の完了 (推定)

2027年12月25日

試験登録日

最初に提出

2026年5月6日

QC基準を満たした最初の提出物

2026年5月6日

最初の投稿 (実際)

2026年5月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月28日

QC基準を満たした最後の更新が送信されました

2026年5月22日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Individual participant data will be available after de-identification.

IPD 共有時間枠

The data will be available immediately after publication

IPD 共有アクセス基準

The data will be available to anyone who wishes and justify to access them

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する